AHNAK2 and central nervous system cancer: The Glioma Centre of Southern Medical University reported a rare case of isocitrate dehydrogenase (IDH) wild-type epithelioid glioblastoma with a BRAF V600E mutation and good results with virofenib treatment, in which the AHNAK2 mutation was identified in the whole exome sequencing results, promising a new target for the treatment of GBM (65).